Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 7 days ago
- 1 min read
26/05/2026
Jade Biosciences announced first participant dosed in Phase 2 trial of JADE101 in IgA Nephropathy (Ref)
Jade Biosciences announced that the first participant had been dosed in the Phase 2, JUNIPER/ NCT07541287, trial which evaluated JADE101(Anti-APRIL) in participants with immunoglobulin A nephropathy (IgAN).
Interim data from JUNIPER were expected in 2027.
Jade Biosciences announced first participant dosed in Phase 1 trial of JADE201 in Rheumatoid Arthritis (Ref)
Jade Biosciences announced that the first participant had been dosed in the first-in human Phase 1/ NCT07533955 trial of JADE201(anti-BAFF-R) in participants with rheumatoid arthritis (RA).
Interim Phase 1 data were expected in 2027.
